Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ299MR)

This product GTTS-WQ299MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Colon sarcoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ299MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2604MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 557
GTTS-WQ14478MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ6428MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ6605MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ13135MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ3944MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ6907MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ2335MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALXN6000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW